Found 27 articles
Cerevance today announced Craig Thompson, chief executive officer (CEO) and Johnna Simões, vice president, corporate development, will participate in panel discussions during the 6th Annual LSX World Congress USA being held in Boston, MA, September 13-14th.
Hemab Therapeutics Presents New Preclinical Research Demonstrating Effects of Its Bispecific Antibody HMB-001 in Factor VII Deficiency
Hemab Therapeutics announced results from preclinical research of HMB-001 in models of factor VII deficiency at the International Society on Thrombosis and Haemostasis 2023 Congress in Montreal.
Hemab Therapeutics to Present New Preclinical Data on HMB-001 in Factor VII Deficiency and Initial Findings from Glanzmann Thrombasthenia Natural History Study at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress
Hemab Therapeutics announced it will present data from preclinical research of HMB-001 in Factor VII deficiency at the upcoming International Society on Thrombosis and Haemostasis 2023 Congress, June 24 – 28, in Montreal.
Mariana Oncology Expands Management Team, Appoints Linda Bain Chief Operating Officer and Chief Financial Officer
Mariana Oncology today announced the appointment of Linda Bain as Chief Operating Officer and Chief Financial Officer.
Legend Biotech Corporation announced the formation of a strategic advisory board and the appointments of Michel Vounatsos, former CEO of Biogen Inc., and John Maraganore, PhD, former CEO of Alnylam Pharmaceuticals, as advisors.
Flare Therapeutics closed Wednesday an oversubscribed Series B funding round, counting $123 million in earnings, which it will use to advance its lead precision oncology asset FX-909 in urothelial cancer.
As the macro pressures of higher rates and fear of recession build, today’s investor is increasingly risk averse. With zero-risk options offering decent returns, only the highest-quality programs will get funding.
Hemab Therapeutics announced the closing of an oversubscribed Series B round to bring new treatment options for lesser-known bleeding disorders.
Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders
Hemab Therapeutics, a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, announced the closing of an oversubscribed $135 million Series B financing.
Hemab Therapeutics Announces First Patient Dosed in Phase 1/2 Study of HMB-001 to Treat Bleeding Disorder Glanzmann Thrombasthenia
Hemab Therapeutics, a clinical-stage biotechnology company developing next-generation therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the first patient has been dosed in a Phase 1/2 study evaluating HMB-001 for the treatment of the severe bleeding disorder Glanzmann Thrombasthenia (Glanzmann).
Xilio Therapeutics, Inc., a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, announced the appointment of Tomas J. Heyman to the company’s board of directors.
Hemab Therapeutics Presents New Data on HMB-001 for the Treatment of Glanzmann Thrombasthenia and Other Bleeding Disorders at 2022 ISTH Congress
Hemab Therapeutics presented new pre-clinical data on HMB-001, a novel bispecific antibody poised to become the first-ever prophylactic treatment option for Glanzmann Thrombasthenia and other rare bleeding conditions.
GNS today announced that John Maraganore, PhD, biopharma industry leader and the former founding CEO of Alnylam Pharmaceuticals, has joined GNS as a strategic advisor.
4/8/2022Onxeo, Amydis, eFFECTOR Therapeutics, Freenome, Urovant Sciences and others all added new guidance and perspectives to their C-suite this week.
Abata Announces Formation of Advisory Board Comprised of Leading Industry Experts in Treg Biology, Cell Therapy and Corporate Development
Abata Therapeutics today announced the formation of the Abata Advisory Board, chaired by Diane Mathis, Ph.D., co-founder of Abata.
Kenneth Frazier, executive chairman and former chief executive officer of Merck, joins former colleagues Roger Perlmutter and Roy Baynes at the well-financed company.
ProQR Therapeutics N.V. today announced that John Maraganore, PhD, biopharma industry leader and the former founding CEO of Alnylam Pharmaceuticals, has joined ProQR as a strategic advisor.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the approval of four generic injectables products.
Recent research supports a link between vitamin D deficiency and severe COVID-19. Here’s a look.
Hemab Therapeutics Announces First Drug Candidate: HMB-001, a Novel Bispecific Antibody with Potential for Treatment of Rare Bleeding Disorders
Preclinical data demonstrate HMB-001's promise as a preventative treatment for patients with underserved bleeding disorders, including Glanzmann Thrombasthenia.